Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis

NCT01755871 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped lack of recruitment

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Fingolimod

Sponsor

Heinrich-Heine University, Duesseldorf

Collaborators

[object Object]